Key result
CRT fails to prevent progression to end-stage hypertrophic cardiomyopathy in a young patient.
Why the study?
Less than 5% of HCM patients develop left ventricular cytological dysfunction and severe heart failure, and treatment options for end-stage disease are limited.
Case Report (n=1)
CRT-D upgrade was unsuccessful in halting disease progression in a patient with end-stage hypertrophic cardiomyopathy, ultimately requiring heart transplant listing.
No takes yet. Share an insight, caveat, or question.
CRT-D upgrade failed to halt progression in this end-stage HCM case; leaves open device therapy role and requires prospective study.
Yoonesi et al. (2022) conducted a case report in Hypertrophic obstructive cardiomyopathy (n=1). Cardiac resynchronization therapy (CRT-D) was evaluated. Cardiac resynchronization therapy was unsuccessful in treating end-stage hypertrophic cardiomyopathy in a 41-year-old woman, whose ejection fraction declined to 5% requiring heart transplant listing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: